Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation.
暂无分享,去创建一个
[1] Charles N. Serhan,et al. Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.
[2] C. Clish,et al. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. , 1998, The Journal of clinical investigation.
[3] C. Patrono,et al. Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. , 2009, Molecular interventions.
[4] M. Holtzman,et al. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. , 1992, The Journal of biological chemistry.
[5] D. Gilroy,et al. Targeting lipoxygenases with care. , 2006, Chemistry & biology.
[6] C. Serhan. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.
[7] C. Serhan,et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors , 2010, Proceedings of the National Academy of Sciences.
[8] J. Haeggström,et al. Chemical modification of leukotriene A4 hydrolase. Indications for essential tyrosyl and arginyl residues at the active site. , 1995, Biochemistry.
[9] P. Libby,et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. , 1995, The Journal of clinical investigation.
[10] P. Ridker,et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[11] C. Clish,et al. Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. , 1998, The Journal of pharmacology and experimental therapeutics.
[12] R. Eglen,et al. Beta galactosidase complementation: a cell-based luminescent assay platform for drug discovery. , 2007, Assay and drug development technologies.
[13] C. Serhan,et al. Resolvins , 2002, The Journal of experimental medicine.
[14] M. Toner,et al. Rapid Appearance of Resolvin Precursors in Inflammatory Exudates: Novel Mechanisms in Resolution1 , 2008, The Journal of Immunology.
[15] B. Samuelsson,et al. Enzyme with dual lipoxygenase activities catalyzes leukotriene A4 synthesis from arachidonic acid. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[16] C. Clish,et al. Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. , 2000, Biochemistry.
[17] J. Uddin,et al. Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.
[18] Yan Lu,et al. Resolvin E 1 Metabolome in Local Inactivation during Inflammation-Resolution 1 , 2008 .
[19] Y. Matsuzawa,et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis , 2007, The Lancet.
[20] D. Gilroy,et al. Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans1 , 2009, The Journal of Immunology.
[21] T. Hla,et al. Human cyclooxygenase-2 cDNA. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[22] P. Calder. The relationship between the fatty acid composition of immune cells and their function. , 2008, Prostaglandins, leukotrienes, and essential fatty acids.
[23] A. Sher,et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.
[24] J. Haeggström. Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis* , 2004, Journal of Biological Chemistry.
[25] Toby Lawrence,et al. Inflammation and cancer: a failure of resolution? , 2007, Trends in pharmacological sciences.
[26] D. Gilroy,et al. 15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation , 2004, The Journal of experimental medicine.
[27] Katherine B Percarpio,et al. Resolvin E2: identification and anti-inflammatory actions: pivotal role of human 5-lipoxygenase in resolvin E series biosynthesis. , 2006, Chemistry & biology.
[28] Sheng-hua Wu,et al. Inverse temporal changes of lipoxin A4 and leukotrienes in children with Henoch-Schönlein purpura. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.
[29] F. Chilton,et al. Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects. , 2003, Clinical therapeutics.
[30] C. Serhan,et al. Endogenous pro‐resolving and anti‐inflammatory lipid mediators: a new pharmacologic genus , 2008, British journal of pharmacology.
[31] Jesper Z. Haeggström,et al. Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation , 2001, Nature Structural Biology.
[32] C. Serhan,et al. Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins1 , 2005, The Journal of Immunology.
[33] Yan Lu,et al. Resolvin E1 Metabolome in Local Inactivation during Inflammation-Resolution1 , 2008, The Journal of Immunology.
[34] C. Clish,et al. Novel Functional Sets of Lipid-Derived Mediators with Antiinflammatory Actions Generated from Omega-3 Fatty Acids via Cyclooxygenase 2–Nonsteroidal Antiinflammatory Drugs and Transcellular Processing , 2000, The Journal of experimental medicine.
[35] R. Flower. The development of COX2 inhibitors , 2003, Nature Reviews Drug Discovery.
[36] William S. Harris,et al. Omega-3 fatty acids: cardiovascular benefits, sources and sustainability , 2009, Nature Reviews Cardiology.
[37] J. Schwab,et al. Resolvin E 1 and Protectin D 1 Activate Inflammation-Resolution Programs , 2009 .
[38] G. FitzGerald,et al. Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. , 2000, The Journal of clinical investigation.
[39] M K Pugsley,et al. The vascular system. An overview of structure and function. , 2000, Journal of pharmacological and toxicological methods.
[40] J. Kutok,et al. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). , 2002, The Journal of pharmacology and experimental therapeutics.
[41] I. Akritopoulou‐Zanze,et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. , 1995, Biochemistry.
[42] J. Haeggström. Leukotriene A 4 Hydrolase / Aminopeptidase , the Gatekeeper of Chemotactic Leukotriene B 4 Biosynthesis * , 2004 .
[43] A. Simopoulos,et al. The Importance of the Omega-6/Omega-3 Fatty Acid Ratio in Cardiovascular Disease and Other Chronic Diseases , 2008, Experimental biology and medicine.
[44] M. Reilly,et al. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. , 2003, The Journal of clinical investigation.
[45] C. Serhan,et al. Lipoxin A4 metabolism by differentiated HL-60 cells and human monocytes: conversion to novel 15-oxo and dihydro products. , 1993, Biochemistry.
[46] Charles N. Serhan,et al. Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.
[47] C. Clish,et al. Anti-microinflammatory lipid signals generated from dietary N-3 fatty acids via cyclooxygenase-2 and transcellular processing: a novel mechanism for NSAID and N-3 PUFA therapeutic actions. , 2000, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[48] C. Serhan,et al. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[49] Charles N. Serhan,et al. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.
[50] E. Corey,et al. Biological Activity of Synthetic Prostaglandins , 1969, Nature.
[51] G. FitzGerald,et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[52] G. Brimhall. The genesis of ores , 1991 .
[53] M. Perretti,et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis , 2009, Nature.
[54] Sheng-hua Wu,et al. Elevated expressions of 15-lipoxygenase and lipoxin A4 in children with acute poststreptococcal glomerulonephritis. , 2009, The American journal of pathology.
[55] C. Clish,et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo , 1999 .
[56] GISSI-Prevenzione Investigators,et al. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial , 1999, The Lancet.
[57] H. Jörnvall,et al. Molecular cloning and amino acid sequence of leukotriene A4 hydrolase. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[58] M. Hamberg,et al. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. , 1984, Proceedings of the National Academy of Sciences of the United States of America.